Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 327 News
1 - 10of about 327 News
March 23, 2023
Not intended for U.S. and UK Media
Bayer expands global clinical program for darolutamide in prostate cancer
READ MORE
March 21, 2023
UN 2023 Water Conference:
Bayer pledges to help tackle global water crisis with new water strategy
READ MORE
March 20, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
READ MORE
March 14, 2023
Bayer collaborates with Microsoft to unveil new cloud-based enterprise solutions, advancing innovation and transparency in the agri-food industry
READ MORE
March 01, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
READ MORE
March 01, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for marketing authorization in Japan
READ MORE
February 28, 2023
Fiscal 2022
Bayer: Significant growth in sales and earnings
READ MORE
February 27, 2023
Not intended for U.S. and UK Media
Nubeqa™ approved for additional indication in Japan
READ MORE
February 10, 2023
Not intended for U.S. and UK Media
Kerendia™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
READ MORE
February 08, 2023
Bill Anderson to become CEO of Bayer AG
READ MORE
1 - 10of about 327 News
1 - 10of about 327 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more